JP2020534270A - １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 - Google Patents

１９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 Download PDF

Info

Publication number
JP2020534270A
JP2020534270A JP2020514950A JP2020514950A JP2020534270A JP 2020534270 A JP2020534270 A JP 2020534270A JP 2020514950 A JP2020514950 A JP 2020514950A JP 2020514950 A JP2020514950 A JP 2020514950A JP 2020534270 A JP2020534270 A JP 2020534270A
Authority
JP
Japan
Prior art keywords
sleep
compound
subject
subjects
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020514950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534270A5 (enExample
Inventor
ジェイムズ ジェイ． ドハーティ，
ジェイムズ ジェイ． ドハーティ，
スティーブン ジェイ ケインズ，
スティーブン ジェイ ケインズ，
ジェフリー エム． ジョナス，
ジェフリー エム． ジョナス，
インダージット カウル，
インダージット カウル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2020534270A publication Critical patent/JP2020534270A/ja
Publication of JP2020534270A5 publication Critical patent/JP2020534270A5/ja
Priority to JP2023008782A priority Critical patent/JP2023038310A/ja
Priority to JP2024091642A priority patent/JP2024107137A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020514950A 2017-09-14 2018-09-14 １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 Pending JP2020534270A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023008782A JP2023038310A (ja) 2017-09-14 2023-01-24 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
JP2024091642A JP2024107137A (ja) 2017-09-14 2024-06-05 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762558703P 2017-09-14 2017-09-14
US62/558,703 2017-09-14
US201862624680P 2018-01-31 2018-01-31
US201862624678P 2018-01-31 2018-01-31
US62/624,680 2018-01-31
US62/624,678 2018-01-31
US201862653189P 2018-04-05 2018-04-05
US62/653,189 2018-04-05
PCT/US2018/051048 WO2019055764A1 (en) 2017-09-14 2018-09-14 C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023008782A Division JP2023038310A (ja) 2017-09-14 2023-01-24 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2020534270A true JP2020534270A (ja) 2020-11-26
JP2020534270A5 JP2020534270A5 (enExample) 2021-10-28

Family

ID=65723895

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020514950A Pending JP2020534270A (ja) 2017-09-14 2018-09-14 １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
JP2023008782A Pending JP2023038310A (ja) 2017-09-14 2023-01-24 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
JP2024091642A Withdrawn JP2024107137A (ja) 2017-09-14 2024-06-05 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023008782A Pending JP2023038310A (ja) 2017-09-14 2023-01-24 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
JP2024091642A Withdrawn JP2024107137A (ja) 2017-09-14 2024-06-05 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Country Status (9)

Country Link
US (3) US20220110949A1 (enExample)
EP (3) EP4218767A1 (enExample)
JP (3) JP2020534270A (enExample)
AU (2) AU2018334214A1 (enExample)
CA (1) CA3075872A1 (enExample)
IL (2) IL303083A (enExample)
MX (3) MX2020002889A (enExample)
TW (2) TW201919642A (enExample)
WO (1) WO2019055764A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230018765A1 (en) * 2019-12-05 2023-01-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517851A (ja) * 2013-04-17 2016-06-20 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170233433A1 (en) * 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517851A (ja) * 2013-04-17 2016-06-20 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EPILEPSIA, vol. 58, no. 2, JPN6022030870, February 2017 (2017-02-01), pages 181 - 221, ISSN: 0005013839 *
INT. J. PHARM. LIFE SCI., vol. Vol.4 Iss.2, JPN6022030873, 2013, pages 2396 - 2401, ISSN: 0005013841 *
J. MED. CHEM., vol. 60, JPN6022030867, July 2017 (2017-07-01), pages 7810 - 7819, ISSN: 0005013838 *
TRENDS PHARMACOL. SCI., vol. 20, no. 3, JPN6022030871, 1999, pages 107 - 112, ISSN: 0005013840 *

Also Published As

Publication number Publication date
US20250387414A1 (en) 2025-12-25
JP2023038310A (ja) 2023-03-16
MX2023010063A (es) 2023-09-06
EP4218767A1 (en) 2023-08-02
EP3681510A1 (en) 2020-07-22
CA3075872A1 (en) 2019-03-21
MX2023010064A (es) 2023-09-06
EP4696301A3 (en) 2026-04-29
AU2024205601A1 (en) 2024-08-29
TW201919642A (zh) 2019-06-01
MX2020002889A (es) 2020-10-01
EP4696301A2 (en) 2026-02-18
WO2019055764A1 (en) 2019-03-21
US20230201224A1 (en) 2023-06-29
JP2024107137A (ja) 2024-08-08
IL303083A (en) 2023-07-01
IL273126A (en) 2020-04-30
AU2018334214A1 (en) 2020-03-26
TW202339764A (zh) 2023-10-16
US20220110949A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
JP2024107137A (ja) １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
Scharf et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.
EA002554B1 (ru) Применение кабэрголина при лечении синдрома усталых ног
Thaxton et al. Sleep disturbances and their management in patients with brain injury
JP2025542596A (ja) 乳分泌中の女性にソルリアムフェトルを投与する方法
AU2020307991A1 (en) Lemborexant for treating sleep issues
JP2007515415A (ja) 不眠症の治療にガボクサドールを使用する方法
JP2007515415A6 (ja) 不眠症の治療にガボクサドールを使用する方法
HK40096830A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
US9622997B2 (en) Methods for treating insomnia
EP3989976A1 (en) Lemborexant for treating sleep issues
JP2025116005A (ja) 睡眠問題の治療のためのレンボレキサント
WO2020263331A1 (en) Lemborexant for treating sleep issues
TW202320783A (zh) 治療與神經系統變性疾病相關的不規律睡眠覺醒節律紊亂和晝夜節律性睡眠障礙之方法
McCall et al. 23 Chapter Movement Disorders in Sleep
JP2026512649A (ja) 疼痛の治療用化合物
WO2026080932A2 (en) Compounds, compositions, and methods of use thereof
KR20250000641A (ko) 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법
KR20100055428A (ko) 수면 장애의 치료
Christian Gillin et al. L-Histidine: Failure to affect the sleep-waking cycle in man
Jacobsen et al. SLEEP DISORDERS
Rama et al. Restless movements legs and syndrome excessive and sleepiness periodic limb
KAPEN MEDICAL TREATMENT OF OBSTRUCTIVE SLEEP APNEA: LIFE-STYLE POSTURAL THERAPY CHANGES, WEIGHT REDUCTION, AND
Parkes et al. Disorders of Sleep and Wakefulness

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220725

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230315